Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346348 | 0.86 | ALDH1A1 (0.47) | ALDH1A1CHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL7371438 | 0.82 | MEN1 (0.51) | ALDH1A1 | |
| SCHEMBL18429014 | 0.81 | CHRM2 (0.45) | OPRD1CHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL18428936 | 0.80 | OPRM1 (0.44) | OPRD1CHRM3OPRM1SIGMAR1OPRK1 | |
| SCHEMBL5969496 | 0.76 | CCR5 (0.53) | OPRD1CHRM2OPRM1SIGMAR1ADRA1A | |
| SCHEMBL28692119 | 0.75 | PGR (0.46) | OPRD1CHRM2OPRM1ADRA1A | |
| SCHEMBL2896994 | 0.74 | L3MBTL3 (0.46) | OPRD1CHRM2CHRM3OPRM1SIGMAR1 | |
| SCHEMBL5969506 | 0.74 | OPRM1 (0.50) | ALDH1A1OPRD1CHRM2CHRM3OPRM1 | |
| SCHEMBL5969537 | 0.74 | CCR5 (0.49) | OPRM1SIGMAR1 | |
| SCHEMBL5969523 | 0.73 | MEN1 (0.49) | CHRM2CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1719770-A2 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| EP-1320529-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053928-A1 | Quinoline derivatives as antibacterials | AAAS, QDPR, QARS1 | ALDH1A1 2974/4885OPRD1 186/4885CHRM2 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.